 |
市场调查报告书
商品编码
1738474
个人化医疗的CRISPR的未来The Future of CRISPR in Personalised Medicine |
||||||
本报告深入探讨了 CRISPR 技术在个人化医疗领域的变革性角色。它深入分析了 CRISPR-Cas9 及相关基因编辑工具如何彻底改变镰状细胞疾病和β地中海贫血等遗传疾病的治疗发展。报告深入分析了 CRISPR 相较于其他基因编辑技术的优点和局限性，以及提高 CRISPR 疗法临床疗效所需应对的挑战。
本报告也探讨了新型 Cas 蛋白、碱基编辑和主要编辑技术以及非病毒递送平台在拓展 CRISPR 治疗潜力方面的影响。报告还强调了基于 CRISPR 的体内和体外疗法在治疗更广泛疾病方面的未来潜力，为应对这一快速发展的领域的医药专业人士提供了宝贵的视角。
关键问题解答
- 1.CRISPR 如何影响个人化医疗的发展？
- 2.与其他基因编辑工具相比，CRISPR-Cas9 有哪些优缺点？
- 3.为了改善以 CRISPR 为基础的疗法的临床应用，需要解决哪些挑战和障碍？
- 4.新型 Cas 蛋白、碱基编辑和 Prime 编辑技术将如何影响基于 CRISPR 的疗法的个人化？
- 5.非病毒递送平台将在基于 CRISPR 的疗法的发展中发挥什么作用？
- 6.基于 CRISPR 的体内和体外疗法在针对更广泛疾病方面有哪些未来潜力？
主要企业
|
|
参加专家清单(摘录)
- Alia Therapeutics基因·工程师(义大利)
- Epicrispr Biotechnologies技术开发部门上级董事(美国)
- Arbor Biotechnologies最高医学负责人(美国)
- SNIPR Biome一起同成立者兼CEO(丹麦)
- Acuitas Therapeutics最高科学负责人(加拿大)
- Arbor Biotechnologies公司最高医学负责人(美国)
- Editas Medicine社长兼CEO(美国)
方法论：
本报告基于独立而简洁的分析，该分析源自于专有的产业研究以及对产业思想领袖的深入访谈。报告深入分析了製药企业高管需要了解的关键发展和市场趋势，以应对未来的机会和挑战。每份报告的重点都基于对二手文献的回顾和已发现的知识缺口。基于这些初步研究，我们制定了基于证据、专家指导的讨论指南，以确保研究能够解答最重要的问题。此外，我们制定了严格的筛选标准，以确保受访者拥有足够的经验、知识和资格就该主题发表意见。
我们的报告有何独特之处？
FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助您掌握新兴趋势，有效应对复杂挑战。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家存取独家访谈和数据，以及持续的市场监测，让您全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域，汇集了包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售与行销、市场准入和其他领域问题的看法，使您能够做出更明智的数据驱动决策，并在快速变化的行业中保持竞争力。
This comprehensive report delves into the transformative role of CRISPR technology in the field of personalised medicine. It provides an in-depth analysis of how CRISPR-Cas9 and associated gene-editing tools are revolutionising the development of therapies for genetic disorders, including sickle-cell disease and beta-thalassemia. Gain insights into the advantages and limitations of CRISPR compared to other gene-editing technologies, as well as the challenges that need to be addressed to enhance the clinical efficacy of CRISPR-based therapies.
The report also explores the impact of novel Cas proteins, base editing and prime editing technologies, alongside non-viral delivery platforms, in expanding the therapeutic potential of CRISPR. Additionally, it highlights future opportunities for in vivo and ex vivo CRISPR-based therapeutics to target a broader spectrum of diseases, offering valuable perspectives for pharmaceutical professionals navigating this rapidly evolving landscape.
Key Questions Answered:
- 1. How has CRISPR impacted the development of personalised medicines?
- 2. What are the advantages and disadvantages of CRISPR-Cas9 compared to other gene editing tools?
- 3. What challenges and obstacles need to be addressed to improve the clinical profile of CRISPR-based therapies?
- 4. How will novel Cas proteins, base editing and prime editing technologies impact the personalisation of CRISPR-based therapies?
- 5. What role do non-viral delivery platforms play in advancing CRISPR-based therapeutics?
- 6. What are the future opportunities for in vivo and ex vivo CRISPR-based therapeutics to target a broader array of diseases?
Key Companies:
|
|
Partial List of Participating Experts:
- Genome Engineer, Alia Therapeutics, Italy
- Senior Director, Head of Technology Development, Epicrispr Biotechnologies, US
- Chief Medical Officer, Arbor Biotechnologies, US
- Co-founder and CEO, SNIPR Biome, Denmark
- Chief Scientific Officer, Acuitas Therapeutics, Canada
- Chief Medical Officer, Arbor Biotechnologies, US
- President and CEO, Editas Medicine, US
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
全球个人化医疗市场研究报告 - 产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年全球女性健康治疗市场研究报告 - 产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年
美国礼宾医疗市场：市场规模、份额、趋势分析（按所有权和专业）、细分市场预测（2025-2030 年）
礼宾医疗市场 - 全球产业规模、份额、趋势、机会和预测，按应用程式、所有权、最终用户、地区和竞争细分，2020-2030 年预测个人化医疗外包市场规模、份额、趋势分析报告：按阶段、最终用途、服务、类型、最终用途、地区、细分预测，2025-2030 年
个人化医疗市场：按产品、应用和最终用户划分 - 全球预测 2025-2030
个人化医疗生物标记市场，规模，占有率，趋势，产业分析报告:各适应症，各用途，各地区 - 市场预测，2025年～2034年
礼宾医疗保健市场规模、份额、成长分析（按专业、按所有权、按地区）- 产业预测，2024-2031 年个人化医疗生物标记市场规模、份额、趋势分析报告：按应用、适应症、地区、细分市场预测，2025-2030个人化医疗市场规模、份额、成长分析、按产品、按应用、按最终用户、按地区 - 行业预测，2024-2031 年